SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.

SG&A Efficiency: Corcept vs. Travere's Strategic Spending

__timestampCorcept Therapeutics IncorporatedTravere Therapeutics, Inc.
Wednesday, January 1, 20143491600059644696
Thursday, January 1, 20153694900079541000
Friday, January 1, 20164524000098015000
Sunday, January 1, 201762416000103958000
Monday, January 1, 201881289000103654000
Tuesday, January 1, 2019100359000128951000
Wednesday, January 1, 2020105326000135799000
Friday, January 1, 2021122356000149883000
Saturday, January 1, 2022152848000220206000
Sunday, January 1, 2023184259000265542000
Loading chart...

Unleashing insights

SG&A Efficiency: A Tale of Two Therapeutics

In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Corcept Therapeutics Incorporated and Travere Therapeutics, Inc. have shown distinct trajectories in their SG&A spending.

Corcept Therapeutics: A Steady Climb

From 2014 to 2023, Corcept's SG&A expenses have grown steadily, increasing by over 400%. This growth reflects their strategic investments in expanding operations and market reach. By 2023, their SG&A expenses reached approximately 184 million, showcasing a consistent upward trend.

Travere Therapeutics: Rapid Expansion

Travere, on the other hand, has experienced a more dramatic rise, with SG&A expenses surging by nearly 345% over the same period. By 2023, their expenses peaked at around 266 million, indicating aggressive expansion and market penetration strategies.

Conclusion

Both companies demonstrate unique approaches to managing SG&A expenses, reflecting their strategic priorities in the evolving pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025